Paroxetine versus other anti-depressive agents for depression.
Andrea Cipriani, Toshi A Furukawa, Antonio Veronese, Norio Watanabe, Rachel Churchill, Hugh McGuire, Corrado Barbui
Author Information
Andrea Cipriani: Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy.
Toshi A Furukawa: Department of Psychiatry & Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Antonio Veronese: Section of Evidence Based Mental Health, Health Service & Population Research Department, Institute of Psychiatry, King's College London, London, UK.
Norio Watanabe: Department of Psychiatry & Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Rachel Churchill: Academic Unit of Psychiatry, Community Based Medicine, University of Bristol, Bristol, UK.
Hugh McGuire: National Coordinating Centre for Women and Child Health, London, UK.
Corrado Barbui: Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy.
This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the efficacy of paroxetine in comparison with other anti-depressive agents in alleviating the acute symptoms of major depressive disorder.To review acceptability of treatment with paroxetine in comparison with other anti-depressive agents.To investigate the adverse effects of paroxetine in comparison with other anti-depressive agents.
References
Ann Pharmacother. 2004 Apr;38(4):579-85
[PMID: 14982982]
Arch Gen Psychiatry. 1962 Dec;7:407-17
[PMID: 13931376]
